000011439 001__ 11439
000011439 005__ 20180208202920.0
000011439 0247_ $$2pmid$$apmid:17409969
000011439 0247_ $$2DOI$$a10.1007/s11943-010-0084-9
000011439 037__ $$aPreJuSER-11439
000011439 041__ $$aeng
000011439 082__ $$a310
000011439 1001_ $$0P:(DE-Juel1)VDB66835$$aKronenberg, T.$$b0$$uFZJ
000011439 245__ $$aErstellung einer Input-Output-Tabelle für Mecklenburg-Vorpommern
000011439 260__ $$aBerlin$$bSpringer$$c2010
000011439 300__ $$a223 - 248
000011439 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000011439 3367_ $$2DataCite$$aOutput Types/Journal article
000011439 3367_ $$00$$2EndNote$$aJournal Article
000011439 3367_ $$2BibTeX$$aARTICLE
000011439 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000011439 3367_ $$2DRIVER$$aarticle
000011439 440_0 $$022961$$aAStA Wirtschafts-und Sozialstatistisches Archiv$$v4$$x1863-8155$$y3
000011439 500__ $$aRecord converted from VDB: 12.11.2012
000011439 520__ $$aThe IRESSA Survival Evaluation in Lung Cancer (ISEL) phase III study compared the efficacy of gefitinib (IRESSA) versus placebo in patients with refractory advanced non-small cell lung cancer (NSCLC). Although a statistically significant difference in survival was not seen between gefitinib and placebo in the overall ISEL population, preplanned subset analyses demonstrated a significant survival benefit in patients who had never smoked and in patients of Asian origin.In ISEL, 1692 patients who were refractory to or intolerant of their latest chemotherapy were randomized to receive either gefitinib (250 mg/day) or placebo, plus best supportive care. Preplanned subgroup analyses included an assessment of patients who were of Asian origin (n = 342).Two hundred thirty-five patients of Asian origin received gefitinib, and 107 received placebo. In these patients, treatment with gefitinib significantly improved survival compared with placebo (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.48, 0.91; p = 0.010; median survival, 9.5 versus 5.5 months). Patients of Asian origin also experienced statistically significant improvements in time to treatment failure with gefitinib compared with placebo (HR, 0.69; 95% CI, 0.52, 0.91; p = 0.0084; 4.4 versus 2.2 months), and objective response rates were higher with gefitinib than with placebo (12 versus 2%). Gefitinib was generally well tolerated in patients of Asian origin, with rash and diarrhea being the most common adverse events. No unexpected adverse events were observed.Treatment with gefitinib was associated with a significant improvement in survival in a subgroup of patients of Asian origin with previously treated refractory advanced NSCLC.
000011439 536__ $$0G:(DE-Juel1)FUEK408$$2G:(DE-HGF)$$aNachhaltige Entwicklung und Technik$$cP26$$x0
000011439 588__ $$aDataset connected to Pubmed
000011439 650_2 $$2MeSH$$aAdult
000011439 650_2 $$2MeSH$$aAged
000011439 650_2 $$2MeSH$$aAged, 80 and over
000011439 650_2 $$2MeSH$$aAntineoplastic Agents: adverse effects
000011439 650_2 $$2MeSH$$aAntineoplastic Agents: therapeutic use
000011439 650_2 $$2MeSH$$aAsian Continental Ancestry Group
000011439 650_2 $$2MeSH$$aCarcinoma, Non-Small-Cell Lung: drug therapy
000011439 650_2 $$2MeSH$$aCarcinoma, Non-Small-Cell Lung: ethnology
000011439 650_2 $$2MeSH$$aCarcinoma, Non-Small-Cell Lung: mortality
000011439 650_2 $$2MeSH$$aDouble-Blind Method
000011439 650_2 $$2MeSH$$aFemale
000011439 650_2 $$2MeSH$$aHumans
000011439 650_2 $$2MeSH$$aLung Neoplasms: drug therapy
000011439 650_2 $$2MeSH$$aLung Neoplasms: ethnology
000011439 650_2 $$2MeSH$$aLung Neoplasms: mortality
000011439 650_2 $$2MeSH$$aMale
000011439 650_2 $$2MeSH$$aMiddle Aged
000011439 650_2 $$2MeSH$$aProtein Kinase Inhibitors: adverse effects
000011439 650_2 $$2MeSH$$aProtein Kinase Inhibitors: therapeutic use
000011439 650_2 $$2MeSH$$aQuinazolines: adverse effects
000011439 650_2 $$2MeSH$$aQuinazolines: therapeutic use
000011439 650_2 $$2MeSH$$aReceptor, Epidermal Growth Factor: antagonists & inhibitors
000011439 650_2 $$2MeSH$$aSurvival Rate
000011439 650_7 $$00$$2NLM Chemicals$$aAntineoplastic Agents
000011439 650_7 $$00$$2NLM Chemicals$$aProtein Kinase Inhibitors
000011439 650_7 $$00$$2NLM Chemicals$$aQuinazolines
000011439 650_7 $$0184475-35-2$$2NLM Chemicals$$agefitinib
000011439 650_7 $$0EC 2.7.10.1$$2NLM Chemicals$$aReceptor, Epidermal Growth Factor
000011439 773__ $$0PERI:(DE-600)2375523-4$$a10.1007/s11943-010-0084-9$$gVol. 4, p. 223 - 248$$p223 - 248$$q4<223 - 248$$tWirtschafts- und sozialstatistisches Archiv$$v4$$x1863-8155$$y2010
000011439 8567_ $$uhttp://dx.doi.org/10.1007/s11943-010-0084-9
000011439 909CO $$ooai:juser.fz-juelich.de:11439$$pVDB
000011439 9131_ $$0G:(DE-Juel1)FUEK408$$bUmwelt$$kP26$$lNachhaltige Entwicklung und Technik$$vNachhaltige Entwicklung und Technik$$x0$$zfortgesetzt als P47
000011439 9132_ $$0G:(DE-HGF)POF3-153$$1G:(DE-HGF)POF3-150$$2G:(DE-HGF)POF3-100$$aDE-HGF$$bForschungsbereich Energie$$lTechnologie, Innovation und Gesellschaft$$vAssessment of Energy Systems  Addressing Issues of Energy Efficiency and Energy Security$$x0
000011439 9141_ $$y2010
000011439 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer review
000011439 9201_ $$0I:(DE-Juel1)VDB815$$d30.09.2010$$gIEF$$kIEF-STE$$lSystemforschung und Technologische Entwicklung$$x0
000011439 970__ $$aVDB:(DE-Juel1)122553
000011439 980__ $$aVDB
000011439 980__ $$aConvertedRecord
000011439 980__ $$ajournal
000011439 980__ $$aI:(DE-Juel1)IEK-STE-20101013
000011439 980__ $$aUNRESTRICTED
000011439 981__ $$aI:(DE-Juel1)IEK-STE-20101013
000011439 981__ $$aI:(DE-Juel1)VDB815